ArticleAging2020
Identification of prognostic immune-related genes in the tumor microenvironment of endometrial cancer.
Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 110 citations in OpenAlex.
- Integrating artificial intelligence and multi-omics data for precision oncology in endometrial cancer: a narrative review.Functional & integrative genomics · 2026Review
- Integrative analysis of tumor-educated platelets for stage-specific diagnosis, prognosis, and therapy in ovarian cancer.Discover oncology · 2026Article
- Tumor-Associated Macrophage-Derived CXCL1 Promotes Endometrial Cancer Progression Through the CXCR2/NF-κB Pathway.Cancer science · 2026Article
- Population and single-cell analyses reveal immune cell-specific expression profiles associated with Alzheimer's disease risk.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- The impact of genomic ancestry on tumor genomics in head and neck squamous cell carcinoma.Cancer metastasis reviews · 2026Review
- Exploration of efferocytosis-related genes as potential therapeutic targets in endometrial cancer.Translational cancer research · 2025Article
- Application of artificial intelligence in assisting treatment of gynecologic tumors: a systematic review.Visual computing for industry, biomedicine, and art · 2025Review
- SIGLEC1 has the potential to be an immune-related prognostic indicator in colon adenocarcinoma: a study based on transcriptomic data and Mendelian randomization analysis.Discover oncology · 2025Article
- Research progress of artificial intelligence in the early screening, diagnosis, precise treatment and prognosis prediction of three central gynecological malignancies.Frontiers in oncology · 2025Review
- Prognostic and predictive significance of the pan-immune-inflammation value in endometrial cancer patients undergoing adjuvant therapy.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Article
- Deciphering ERR family genes as prognostic and immunological biomarkers through pan-cancer analysis with validation in gallbladder cancer.Frontiers in oncology · 2025Article
- CRISPR-Cas9 screening identified novel subtypes of cutaneous melanoma based on essential cancer genes.Archives of dermatological research · 2024Article
- Review
- The Deep Proteomics Approach Identified Extracellular Vesicular Proteins Correlated to Extracellular Matrix in Type One and Two Endometrial Cancer.International journal of molecular sciences · 2024Article
- Comprehensive analysis of a NAD+ metabolism-derived gene signature to predict the prognosis and immune landscape in endometrial cancer.Biomolecules & biomedicine · 2024Article
- PTPRC functions as a prognosis biomarker in the tumor microenvironment of cutaneous melanoma.Scientific reports · 2023Article
- Re-stratification of patients with copy-number low endometrial cancer by clinicopathological characteristics.World journal of surgical oncology · 2023Article
- Down regulation of Cathepsin W is associated with poor prognosis in pancreatic cancer.Scientific reports · 2023Article
- Novel insights into tumorigenesis and prognosis of endometrial cancer through systematic investigation and validation on mitophagy-related signature.Human cell · 2023Article
- High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancer.Journal of cancer research and clinical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer (EC) is one of the most common gynecologic malignancies. To identify potential prognostic biomarkers for EC, we analyzed the relationship between the EC tumor microenvironment and gene expression profiles. Using the ESTIMATE R tool, we found that immune and stromal scores correlated with clinical data and the prognosis of EC patients. Based on the immune and stromal scores, 387 intersection differentially expressed genes were identified. Eight immune-related genes were then identified using two machine learning algorithms. Functional enrichment analysis revealed that these genes were mainly associated with T cell activation and response. Kaplan-Meier survival analysis showed that expression of TMEM150B, CACNA2D2, TRPM5, NOL4, CTSW, and SIGLEC1 significantly correlated with overall survival times of EC patients. In addition, using the TIMER algorithm, we found that expression of TMEM150B, SIGLEC1, and CTSW correlated positively with the tumor infiltration levels of B cells, CD8+ T cells, CD4+ T cells, macrophages, and dendritic cells. These findings indicate that the composition of the tumor microenvironment affects the clinical outcomes of EC patients, and suggests that it may provide a basis for development of novel prognostic biomarkers and immunotherapies for EC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.